FGFR inhibitors, in combination with standard treatments, have extended the lives of many with this disease. However, these drugs often stop working after six to eight months.
“These drugs work very well for a while, but resistance is inevitable,” says gastrointestinal medical oncologist Milind Javle, M.D.
Now, a new type of FGFR inhibitor may allow patients to live longer without their disease progressing.
Comments are closed.